- Medical Education
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- Q&A Archive
- The Dean's Perspective
- Harvard Mahoney Neuroscience Institute
- Human Resources
- Contact us
- Dental Medicine
- Harvard University
Molecule battles drug-resistant cancer
September 18, 2012
A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers have found.
In a study published online in Cancer Cell, the investigators report that the small molecule P5091 triggered apoptosis—programmed cell death—in drug-resistant myeloma cells grown in the laboratory and in animals. The anti-myeloma effect was even more powerful when researchers combined P5091 with other therapies.
"Velcade was one of the first in a class of drugs known as proteasome inhibitors to be approved by the U.S. Food and Drug Administration for multiple myeloma treatment," said Dharminder Chauhan, HMS principal associate in medicine at Dana–Farber Cancer Institute, and lead author of the paper with Ze Tian, HMS instructor in medicine, also at Dana–Farber.
"While Velcade is successful in many patients with multiple myeloma, it often loses its effectiveness over time, which prompted us to seek other drug targets," Chauhan said.
The study’s senior author, Kenneth Anderson, HMS Kraft Family Professor of Medicine at Dana–Farber, is one of four researchers awarded the 2012 Warren Alpert Foundation Award for the development of Velcade.
The proteasome acts as a cell's "garbage disposal," chewing up and disposing of unwanted proteins. Inhibiting the proteasome causes an accumulation of waste proteins that spurs cancer cell death.
The proteasome is also part of a larger mechanism known as the ubiquitin proteasome system, or UPS. The system functions in two ways: It can attach small proteins known as ubiquitins to cell proteins, thereby marking those proteins for disposal by the proteasome, or it can remove ubiquitins, thus sparing the proteins from disposal.
"Dysfunction of the UPS has been linked to the development of many human diseases, including cancer, and is a valid target for therapy," Chauhan said.
A variety of enzymes help affix or remove ubiquitin from proteins. In the current study, investigators focused on a remover—a "deubiquitylator" known as USP7. Studies have shown that USP7 acts on many cancer-related proteins. By breaking down proteins that restrain cancer cell growth, USP7 allows tumors to grow unabated. Patients with high levels of USP7 in their myeloma cells tend to have poorer survival rates.
In the Cancer Cell study, researchers tested whether P5091, a small-molecule inhibitor of USP7 that was synthesized by Progenra, Inc., could cause the death of myeloma cells that had developed resistance to Velcade and other current therapies.
"Blocking USP7 decreases the level of a cancer-promoting protein called HDM2, which has the effect of bolstering p53 and p21, a gene that suppresses tumor cell growth," Chauhan said. "The result is that tumor cells stop growing and begin to die."
"In laboratory cell cultures, P5091 resulted in the death of myeloma cells," said Anderson, who is also director of the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics at Dana–Farber. "In animal models of myeloma, this molecule impaired tumor growth, prolonged survival and didn't harm normal tissue.”
When researchers combined P5091 with the drugs lenalidomide, SAHA or dexamethasone, the myeloma-killing effects were even more pronounced.
Although P5091 itself has not been formulated into a drug, the study demonstrates "that you can target molecules in the ubiquitin-proteasome system without targeting the proteasome itself, and still achieve a cancer cell–killing effect with no significant toxicity," Chauhan said. "Our results laid the groundwork for testing USP7 inhibitors, either alone or in combination with other drugs, in patients with multiple myeloma.”
Based on the study results, Progenra plans to help lead studies of USP7 inhibitors in future clinical trials.
Funding for the study was provided in part by grants from the National Institutes of Health (P50100707, PO1-CA078378, R4DK071391 and R43CA115205).
Adapted from a Dana-Farber Cancer Institute news release.